Thu, February 1, 2018
Wed, January 31, 2018
Tue, January 30, 2018
Mon, January 29, 2018
Fri, January 26, 2018
Thu, January 25, 2018
Wed, January 24, 2018
Tue, January 23, 2018
Mon, January 22, 2018
Fri, January 19, 2018
Thu, January 18, 2018
Wed, January 17, 2018
Tue, January 16, 2018
Fri, January 12, 2018

Paul Matteis Maintained (ALNY) at Hold with Increased Target to $135 on, Jan 25th, 2018


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-135-on-jan-25th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $132 to $135 on, Jan 25th, 2018.

Paul has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $130 on, Thursday, November 9th, 2017


These are the ratings of the 6 analyists that currently disagree with Paul


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy on, Thursday, November 9th, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $158 on, Wednesday, November 8th, 2017
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $220 on, Wednesday, November 8th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $151 on, Friday, November 3rd, 2017
  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017
  • Terence Flynn of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Monday, October 2nd, 2017

Publication Contributing Sources